Effect of Acetazolamide on Subclinical High-Altitude Pulmonary Edema Detected by Lung Ultrasonography

Stopped early · Phase 4 · Has a placebo group

Conditions studied: High Altitude Pulmonary Edema

In brief

The overall goal of this study is to detect preclinical signs of HAPE by lung ultrasonography and evaluate the effectiveness of acetazolamide at decreasing pulmonary edema by using ultrasound.

Key facts

Study ID

NCT03490916

Run by

Vincent Kan

People needed

18

Starts

2018-03-23

Expected to finish

2018-04-04

Last updated by the study team

2019-05-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• At least 18 years of age
• Able to consent
• English speaking
• Trekking directly to Everest Base Camp

You may not qualify if…

• Age less than 18 years
• Non-English speaking
• Pregnant
• Already had a diagnosis of acute mountain sickness, high-altitude cerebral edema, or high-altitude pulmonary edema
• Been on a high-altitude trek 2 weeks prior to this study
• Has taken acetazolamide 1 week prior to start of trek
• Has a sulfa allergy
• Has any type of acute or chronic pulmonary conditions

Where it is running

• UMass Medical School — Worcester, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.